Why the study?
Does targeting higher intraoperative blood pressures reduce adverse cardiovascular events in patients at cardiac risk undergoing major noncardiac surgery?
Does targeting higher intraoperative blood pressures reduce adverse cardiovascular events in patients at cardiac risk undergoing major noncardiac surgery?
Universally targeting higher intraoperative blood pressures does not reduce postoperative cardiovascular complications or acute kidney injury in noncardiac surgery.
Answers are grounded in this paper and cite their sources.
Targeting higher intraoperative MAP does not reduce MACE or AKI; challenges routine liberal BP targets in noncardiac surgery.
These findings do not support universally targeting higher intraoperative blood pressures to reduce postoperative complications. Despite a 60% reduction in hypotensive time with MAP <65 mm Hg, no significant reductions in acute myocardial injury or 30-day MACE/AKI could be found. (Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery [BBB]; NCT02533128).
No takes yet. Share an insight, caveat, or question.
Wanner et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: